<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02627859</url>
  </required_header>
  <id_info>
    <org_study_id>13DUR502</org_study_id>
    <nct_id>NCT02627859</nct_id>
  </id_info>
  <brief_title>26 Week Open Label Study Evaluating Single IA Injection of DUROLANE SJ for Treatment of Osteoarthritis Pain of the Ankle</brief_title>
  <official_title>A 26 Week Multicenter Prospective Open Label Clinical Study Evaluating a Single Intra-articular Injection of DUROLANE SJ1ml for Treatment of OA Pain of the Ankle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioventus LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioventus LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      26 week open label study of treatment with Durolane for OA pain of the ankle&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single injection Durolane in patients with mild to moderate OA of the ankle.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AOS pain subscale score</measure>
    <time_frame>at 26 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Durolane SJ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durolane SJ intra-articular injection; device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Durolane SJ</intervention_name>
    <description>1ml single intra-articular injection in ankle</description>
    <arm_group_label>Durolane SJ</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Females or males between the ages of 19 and 85 years of age&#xD;
&#xD;
          2. Diagnosis of mild to moderate (K-L grade II or III) osteoarthritis (OA) of the study&#xD;
             ankle joint, confirmed by radiographs taken within the previous six months OA in the&#xD;
             contralateral ankle is permissible provided that OA symptoms are greater in the study&#xD;
             ankle.&#xD;
&#xD;
          3. VAS (100mm) AOS pain subscale score in the range of 30mm to 90mm for the study ankle&#xD;
&#xD;
          4. Must be willing to discontinue use of oral and topical analgesia other than rescue use&#xD;
             of acetaminophen for any pain including OA pain in the study ankle. Must also be&#xD;
             willing to discontinue acetaminophen rescue medication for at least 24 hours before&#xD;
             each study visit&#xD;
&#xD;
          5. Abstinence from any IA or peri-articular injections in the study ankle during the&#xD;
             course of the trial, except for the Investigational Product&#xD;
&#xD;
          6. Cooperative and able to communicate effectively with the Investigators&#xD;
&#xD;
          7. Patients with chronic ankle pain of the study ankle lasting more than 6 months without&#xD;
             clinically significant improvement in ankle pain over the past one month&#xD;
&#xD;
          8. Body mass index (BMI) â‰¤ 35 kg/m2.&#xD;
&#xD;
          9. English literacy and ability to understand and complete all informed consent&#xD;
             procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Significant pain from other joints or low back pain requiring chronic ongoing&#xD;
             analgesic therapy&#xD;
&#xD;
          2. Hindfoot deformities&#xD;
&#xD;
          3. Substantial venous or lymphatic stasis in the legs&#xD;
&#xD;
          4. Presence of one or more conditions that could confound pain and functional assessments&#xD;
             in the study ankle, e.g., plantar fasciitis, Achilles tendonitis, sprains of the foot,&#xD;
             or degenerative joint disease of the foot.&#xD;
&#xD;
          5. Clinically-apparent tense effusion, signs of misalignment or instability in the study&#xD;
             ankle&#xD;
&#xD;
          6. Ankle x-ray findings of acute fractures, severe loss of bone density, avascular&#xD;
             necrosis and/or severe deformity in the study ankle&#xD;
&#xD;
          7. Surgery to the study ankle within the previous 12 months&#xD;
&#xD;
          8. Unable to abstain treatment with NSAIDs or any pain management medications during the&#xD;
             week (or five half-lives of the drug, whichever is longer) prior to Baseline Visit.&#xD;
&#xD;
          9. Unable to abstain from treatment with topical analgesics during the washout period&#xD;
             prior to screening visit and throughout the duration of the study. Washout period for&#xD;
             topical analgesics is based on clinical investigator judgment (~ a few days).&#xD;
&#xD;
         10. Inability to tolerate acetaminophen for rescue medication use.&#xD;
&#xD;
         11. IA or local peri-articular corticosteroid injections to the study ankle within the&#xD;
             previous three months; or to any other joint within the previous month; or any oral&#xD;
             corticosteroid within the previous month. Steroid inhalants are permitted if the&#xD;
             patient has been on a stable regimen for the past month and remains on this regimen&#xD;
             throughout the course of the trial&#xD;
&#xD;
         12. IA injections with hyaluronic acid in the study ankle within the last 9 months&#xD;
&#xD;
         13. Previous allergic reaction to a HA or lidocaine product allergies.&#xD;
&#xD;
         14. Treatment with glucosamine/chondroitin sulfate initiated within the past three months,&#xD;
             or dosage not stable for the past three months&#xD;
&#xD;
         15. Change in physical therapy for the study ankle within one month preceding screening,&#xD;
             or expected change in physical therapy for the ankle during the study&#xD;
&#xD;
         16. Planned surgical procedure during the study period.&#xD;
&#xD;
         17. Previous history or presence of septic arthritis in study ankle&#xD;
&#xD;
         18. Active skin disease or infection in the area of the injection site&#xD;
&#xD;
         19. Alcohol or drug abuse as determined by the Investigator or use of alcohol for control&#xD;
             of pain; Use of illicit drugs including cannabis.&#xD;
&#xD;
         20. Systemic inflammatory condition or autoimmune disease or infection such as rheumatoid&#xD;
             arthritis, inflammatory arthritis, ankylosing spondylitis, psoriatic arthritis,&#xD;
             reactive arthritis, gout/ acute pseudo gout or any other connective tissue disease&#xD;
&#xD;
         21. Uncontrolled hypothyroidism&#xD;
&#xD;
         22. Treatment with anticoagulant (except for acetylsalicylic acid maximum of 325mg/day)&#xD;
&#xD;
         23. Any medical condition which in the opinion of the investigator makes the patient&#xD;
             unsuitable for inclusion (e.g., severe progressive chronic disease, malignancy,&#xD;
             bleeding disorder, fibromyalgia)&#xD;
&#xD;
         24. Pregnant or breast-feeding woman or woman of child-bearing potential not practicing&#xD;
             adequate contraception.&#xD;
&#xD;
         25. Subjects that in the opinion of the investigator are unsuitable for inclusion (e.g.,&#xD;
             subjects not likely to avoid other therapies, subjects not likely to stay in the study&#xD;
             or with plans to relocate during the whole study period, or subjects likely to be&#xD;
             unreliable)&#xD;
&#xD;
         26. Concurrent participation in any other clinical study or participation within the&#xD;
             preceding 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alistair Younger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Pauls Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Providence Health Care</name>
      <address>
        <city>Vancouver,</city>
        <state>British Columbia</state>
        <zip>V6Z-2A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>December 8, 2015</study_first_submitted>
  <study_first_submitted_qc>December 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2015</study_first_posted>
  <last_update_submitted>September 20, 2016</last_update_submitted>
  <last_update_submitted_qc>September 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>February 12, 2021</submitted>
    <returned>March 3, 2021</returned>
    <submitted>March 8, 2021</submitted>
    <returned>April 1, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

